Palvella Therapeutics will present three poster presentations featuring new data in microcystic lymphatic malformations and disseminated superficial actinic porokeratosis (DSAP) at Fall Clinical Dermatology 2026.

The company announced the poster lineup, which spans two rare dermatologic conditions with significant unmet treatment needs. The announcement signals expanding clinical activity for Palvella across both indications.

Why does this matter for dermatologists?

Microcystic lymphatic malformations and DSAP are rare, chronic skin disorders with few approved therapeutic options. New data presentations at a major clinical meeting offer practicing dermatologists a first look at emerging evidence that could shape future management of these conditions.

Fall Clinical Dermatology is a recurring venue for late-breaking and practice-relevant dermatology research. Palvella's decision to bring three posters to the 2026 edition indicates a growing dataset across its pipeline programs targeting these two indications.

What comes next?

Poster presentations at Fall Clinical Dermatology 2026 will make the full datasets available to attendees, with peer-reviewed publication typically following. Dermatologists treating patients with microcystic lymphatic malformations or DSAP should watch for the detailed results as they emerge from the meeting.